Robert Lustig, MD: What GLP-1 Drugs Don’t Fix—Sugar, Metabolism & Dementia - Podcast at Emery Pharma

It was a great pleasure welcoming my friend and colleague, Professor Robert Lustig, M.D., back to Emery Pharma for another warm, candid, and scientifically engaging conversation. Dr. Lustig is internationally recognized for his work on metabolic health and for his ability to explain complex medical and scientific concepts in a clear, compelling, and thought-provoking manner. During this wide-ranging discussion, we explored several important and timely health topics, including GLP-1 medications and how they affect appetite, weight loss, insulin secretion, and the brain’s reward system. We also discussed the potential benefits and limitations of these medications, including gastrointestinal side effects, muscle loss, treatment costs, and the tendency for weight to return after the medication is discontinued. Our conversation also examined the effects of sugar, fructose, and ultra-processed foods on metabolic health, beginning as early as pregnancy and infancy. Dr. Lustig shared his perspective on how diet can influence the microbiome, insulin resistance, fatty-liver disease, inflammation, and the long-term risk of chronic illness. Other subjects included vitamin D and whether supplementation alone is sufficient; cortisol and the physiological consequences of chronic stress; and the relationship between mitochondrial function, cellular energy production, and dementia. We concluded by discussing the progression of fatty-liver disease and the importance of addressing excess sugar consumption, alcohol intake, sleep, exercise, and stress before irreversible damage develops. Dr. Lustig brings tremendous scientific knowledge, passion, and intellectual curiosity to every conversation. I sincerely enjoyed our discussion and hope you find it equally informative, practical, and stimulating. I invite you to watch the full podcast and share your thoughts in the comments. About Emery Pharma Emery Pharma is deeply committed to advancing public health and exclusively focuses on projects that enhance the well-being of both individuals and the environment. As a comprehensive contract research laboratory, Emery Pharma provides extensive support across the entire spectrum of pharmaceutical development, covering small molecule drugs, biologics, biosimilars, gene therapy, botanicals, and more. Emery Pharma's array of premium services includes analytical and bioanalytical solutions, microbiology and cell biology services, drug and impurity characterization, and comprehensive R&D with cGMP/GLP support. The Emery Pharma team excels in customizing innovative solutions tailored to the unique requirements of each client. They seamlessly oversee the entire process, from initial drug discovery to thorough data analysis and insights generation. Their expertise allows them to tackle scientific challenges proactively, ensuring clients avoid unnecessary setbacks. Emery Pharma's accomplished chemists and biologists harness state-of-the-art technology, encompassing cutting-edge tools such as high-resolution mass spectrometry (Orbitrap), triple quad LC-MS/MS, GC-MS, preparative HPLC, and 400 MHz multinuclear NMR. For further details, please don't hesitate to reach out to Emery Pharma at [email protected] or explore their website at: emerypharma.com